The First Drug That Might Let Celiac Patients Eat a Breadstick
Celiac disease affects 2 million Americans, and the only treatment is avoiding gluten forever. Teva just posted Phase 2 data showing its antibody TEV-408 can cut gluten-induced gut damage roughly in half, a first for a field with zero approved targeted therapies.
Imagine being allergic to birthday cake, pasta night, and basically every restaurant menu. That's life with celiac disease. Your immune system treats gluten like an invader, shredding your intestinal lining every time you eat a slice of bread. The only "treatment" for 2 million Americans? Avoid gluten. Forever.
No targeted drug has ever been approved for celiac disease. Not one.
Teva Pharmaceutical just posted Phase 2 data suggesting that might finally change.
A Tiny Trial With Outsized Implications
Teva's antibody candidate, TEV-408, works by blocking a protein called interleukin-15 (IL-15). Think of IL-15 as the alarm bell your immune system rings when gluten shows up. It rallies immune cells to attack the intestinal lining, causing the inflammation and damage that define celiac disease. TEV-408 is designed to muffle that alarm.
The Phase 2a trial enrolled 50 adults with celiac disease who were already on a gluten-free diet. Each patient received a single injection of TEV-408 (or placebo), then did something that would normally terrify them: they ate gluten every day for six weeks straight.
The main question was simple. Would their intestines survive the gluten challenge better than placebo?
The Results: Guts Protected
To measure intestinal damage, researchers used something called the villous height-to-crypt depth ratio (Vh:Cd). Your small intestine is lined with tiny, finger-like projections called villi that absorb nutrients. In celiac patients exposed to gluten, those villi get flattened and destroyed. The Vh:Cd ratio captures how badly that's happening; a bigger drop means more damage.
Patients on placebo saw their ratio drop by 0.88. Patients on TEV-408 dropped only 0.43. That's roughly half the intestinal damage, and the difference was statistically significant (p<0.05).
A second measure told an even cleaner story. Intraepithelial lymphocytes (IELs), the immune cells that pile into the gut lining during a celiac flare, surged by in the placebo group. In the TEV-408 group? They barely budged, rising just . It's the difference between a riot and a quiet Tuesday.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
27.60
0.37
Teva also reported that patients on TEV-408 had lower gastrointestinal symptom scores, though full numerical details haven't been released yet. And critically, the drug was well tolerated with no new safety signals.
Why "No Approved Therapy" Is Such a Big Deal
Celiac disease affects roughly 1% of the global population. In the U.S. alone, about 2 million people have it, and a meaningful share don't even know it yet. The condition is chronic, potentially serious (think malnutrition, osteoporosis, increased lymphoma risk), and maddeningly hard to manage.
The gluten-free diet sounds straightforward until you realize gluten hides in soy sauce, salad dressings, medications, and communion wafers. Even patients who try their hardest often get accidental exposure. Studies show that strict dietary adherence doesn't fully prevent ongoing intestinal inflammation in many patients.
So the unmet need isn't theoretical. It's a massive gap in modern medicine: a common, well-understood autoimmune disease with zero approved targeted treatments. For drug developers, that's a wide-open market with no incumbent to unseat.
Teva Isn't the Only One Circling
The celiac pipeline has quietly exploded, with 30+ candidates from over 25 companies in various stages of development. The approaches range from gluten-degrading enzymes (break down gluten before it causes trouble) to immune tolerance therapies (retrain the immune system to ignore gluten) to targeted antibodies like TEV-408.
Some notable competitors include Sanofi's amlitelimab (a Phase 2 OX40 ligand inhibitor for nonresponsive celiac), Takeda's TAK-227 (a Phase 2 oral TG2 inhibitor), and Barinthus Biotherapeutics' VTP-1000 (a Phase 1 vaccine-like approach with MAD data expected in the second half of 2026). Anokion's KAN-101 is another notable program, with reported positive Phase 2 data on immune tolerance for celiac disease and ongoing clinical trials.
The competitive field is crowded but fragile. Most programs are still in Phase 1 or early Phase 2, and the highest-profile late-stage attempt in the space (larazotide acetate, a tight-junction modulator) was discontinued in Phase 3 after an interim futility analysis. Celiac drug development has a history of promising science crashing into clinical reality.
That context makes Teva's clean Phase 2a win more meaningful. It's not just positive data; it's proof that targeted immunology can actually protect the gut from gluten-driven damage in a controlled setting.
The Bigger Picture for Teva
This isn't a one-off bet. Teva has been quietly building an immunology franchise as part of a broader "pivot to growth" strategy aimed at creating a $5 billion innovative medicines business by 2030.
TEV-408 is the centerpiece. Beyond celiac disease, Teva plans to move the drug into a Phase 2b vitiligo study in Q4 2026, and the FDA has already granted it fast-track designation. To fund development without straining its balance sheet, Teva struck a deal with Royalty Pharma worth up to $500 million, with $75 million upfront and additional payments tied to Phase 3 progress.
Meanwhile, Teva's other big immunology asset, duvakitug (an anti-TL1A antibody partnered with Sanofi), entered Phase 3 trials for ulcerative colitis and Crohn's disease in late 2025. The pattern is clear: Teva is using partnerships and creative financing to build a serious autoimmune portfolio without the megamerger approach favored by bigger pharma players.
Wall Street's Verdict: Cautiously Excited
Teva shares climbed roughly 3% in early trading after the data dropped. Scotiabank analyst Louise Chen called the celiac results, combined with earlier vitiligo data, an "exciting contributor" to Teva's innovative pipeline.
But the market reaction was measured, not euphoric, and for good reason. This is still a 50-patient study. The primary endpoint, while statistically significant, will need to hold up in larger, longer trials. And translating biopsy-based endpoints into symptom improvement that patients and regulators find compelling is a challenge the entire celiac field has struggled with.
The data de-risks the IL-15 hypothesis. It doesn't guarantee a drug. Teva now faces the harder part: designing a pivotal trial that proves TEV-408 doesn't just protect villi in a controlled gluten challenge, but meaningfully improves the daily lives of celiac patients in the real world.
For the millions of people who scan every ingredient label and dread every shared kitchen, though, this is the most encouraging clinical result the field has produced. A future where celiac disease has an actual treatment, not just a diet, is starting to look possible.
Clinical & Regulatory4 min read
A Blood Pressure Drug Just Slowed Lung Scarring. Wait, What?
United Therapeutics' Tyvaso, already approved for pulmonary hypertension, just aced two Phase 3 trials in a completely different disease: the deadly lung-scarring condition IPF. The results are reshaping a competitive landscape that patients desperately need shaken up.
